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S tudy of the cardiovascular effects of glucagon in man have shown a posi- 
tive inotropic and chronotropic effect re- 
sulting in an increase in cardiac output.1-3 
These effects occur one to 3 minutes after 
the intravenous injection of 3 to 5 mg. of 
glucagon and are dissipated in 30 minutes. 
These effects are similar to those of isopro- 
terenol; however, glucagon has a limited 
chronotropic effect in man’ and has not 
caused arrhythmias even in the presence 
of digitalis.2 In contrast, a recent study of 
patients with chronic valvufar heart dis- 
ease concluded that these cardiac effects 
were variable, not dose-related, and of 
small magnitude when present.4 In addition 
to these cardiac effects, glucagon has been 
shown to increase renal excretion of water 
and electrolytes.6 Since previous studies 
are limited to the observation of the effects 
of a single bolus injection, given to patients 
who were not in stress situations, it seemed 
appropriate to study the feasibility and 
efficacy of a continuous infusion of gluca- 
gon over a period of days in the treatment 
of conditions with low cardiac output or 
cardiogenic shock. 
Methods 
Lyophilized glucagon (Eli Lilly & Co.) 
was mixed with diluent and a small volume 
of 5 per cent glucose and water and placed 
in an in-line burette with an administra- 
tion set adapter* to carefully control fluid 
volume and glucagon dosage. Since solu- 
tions of glucagon deteriorate at room tem- 
perature, these solutions were prepared 
fresh every hour. When potassium sup- 
plement was required, 20 mEq. of KC1 
was given orally or added to the intra- 
venous A uids. Standard clinical techniques 
were used to record blood pressure and 
fluid balance. Blood glucose, serum Na+, 
K+, Cl-, HCOs-, Ca++, creatinine, and 
blood urea nitrogen were determined with 
standard techniques in the clinical pa- 
thology laboratories. 
Table I lists the basic cardiac diagnosis 
and the clinical state of each patient at the 
time glucagon infusion was started as well 
as their response to therapy. Sixteen pa- 
tients received 18 glucagon infusions at an 
average rate of 4.0 mg. per hour (1 to 16 
mg. per hour) for an average treatment 
period of 4.9 days (0.1 to 12 days). All 
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patients were receiving digitalis. Only 2 
of the 16 patients received diuretic agents 
during the first 24 hours of glucagon in- 
fusion. Cases 4 and 5 were on maintenance 
diuretics before and during the glucagon 
infusion and the dosage was not changed. 
Nine patients received diuretics later in 
the course of glucagon therapy to effect 
further diuresis during glucagon support of 
cardiac function. 
Results 
Blood pressure (Fig. 1). Five patients had 
no obtainable blood pressure at the time 
glucagon was started and 9 additional 
patients had systolic pressures of 90 mm. 
Hg or lower. Twelve of these 14 patients 
responded to glucagon with an increase in 
blood pressure. Two patients (Nos. 6 and 
12) were in irreversible shock, unresponsive 
to vasopressors, for 14 and 12 hours, re- 
spectively, before glucagon was started and 
died 6 and 2% hours, respectively, after 
starting glucagon with no change in any 
parameter. One patient had severe hypo- 
tension reversed with isoproterenol in- 
fusion, but because of tachycardia (140 
per minute) and oliguria she was switched 
to glucagon with maintenance of blood 




Systolic Blood Pressure 
decrease in heart rate. Two patients with 
normal blood pressures received glucagon 
therapy and there was no change in blood 
pressure or evidence of clinical improve- 
ment in their signs and symptoms of con- 
gestive heart failure. 
The mean increase in systolic blood pres- 
sure was 34 mm. Hg (p < 0.01) and the 
mean increase in diastolic pressure was 
28 mm. Hg (p < 0.01). The increase in 
blood pressure was seen within 15 minutes 
in 4 patients and as late as 90 minutes in 
one patient. 
Urine output (Fig. 2). All patients who 
improved clinically had an increase in urine 
output. The mean urine output for the 8 
hours before glucagon was 149 C.C. and for 
the first 8 hours on glucagon was 430 c.c., 
an average increase of 282 C.C. (p < 0.01). 
This 16 hour period was selected since no 
diuretic or other therapy was given or 
changed during this period which could 
have influenced this response to glucagon. 
Heart rate and rhythm (Fig. 2). Six pa- 
tients had atria1 fibrillation as their basic 
rhythm, 9 had sinus tachycardia, and one 
had normal sinus rhythm (80 per minute). 
The mean ventricular rate before glucagon 
was 107 per minute. One patient had an 
increase in the ventricular rate from 70 to 
lz&-Y&- 
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Fig. 1. Glucagon produced a significant (p < 0.01) increase in systolic and diastolic blood pressure. 
















Total Eight hr. Urine Output Ventricular Rate 
Fig. 2. Glucagon produced a significant increase in urine output (p < 0.01) and a decrease in ventricular rate 





Serum K* Without Supplement 
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Before 
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Serum K’ With Supplement 
Fig. 3. Glucagon produced a decrease in serum potassium which can be prevented by giving I(C1 supplements 
with the initial infusion. 
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80 per minute, 3 patients were unchanged, 
and all the other patients had a decrease 
in ventricular rate. The mean ventricular 
rate during glucagon therapy was 93 per 
minute, a decrease of 14 per minute (p < 
0.01). 
Five patients had paroxysmal arrhyth- 
mias during the 24 hours before glucagon 
was started. One patient had paroxysmal 
atria1 tachycardia (PAT) with block due to 
digitalis toxicity, one had paroxysms of 
atria1 fibrillation, and 3 had paroxysms of 
ventricular tachycardia. These patients 
had no paroxysmal arrhythmias during 
glucagon therapy. 
Serum electrolytes (Fig. 3). In 4 patients 
glucagon infusion was instituted without 
potassium supplements. The mean serum 
potassium before glucagon was 4.S mEq. 
per liter and within 6 hours the mean potas- 
sium was 3.2 mEq. per liter. All of the 
other patients had 20 mEq. of KC1 along 
with the initial infusion of glucagon, and 
there was no significant change in serum 
potassium, 4.3 mEq. per liter before gluca- 
gon and 4.2 mEq. per liter after glucagon 
was started. Three patients developed hy- 
perkalemia of 7.7, 6.6, and 8.0 mEq. per 
liter on the third, seventh, and fifth days 
of glucagon infusions with KC1 supple- 
ments which required discontinuing potas- 
sium and treatment with exchange resins. 
Two of these patients had failed to improve 
with glucagon and had deteriorating renal 
function with rising serum creatinines to 
3.5 and 4.9 mg. per cent, respectively. The 
third patient was receiving 120 mEq. of 
KC1 supplements daily but had normal 
renal function studies and good urine out- 
put, and the reason for the hyperkalemia 
was not clear. There was no significant 
change in other serum electrolytes. 
Blood glucose. Fifteen patients had no 
known abnormality of glucose tolerance 
and one patient had diabetes mellitus. 
The mean f one standard deviation of all 
blood sugar determinations made in non- 
diabetic patients while receiving glucagon 
was 151 f 32 mg. per cent. None of these 
patients required therapy for hypergly- 
cemia. Patient 10 was a known diabetic 
controlled with oral hypoglycemic agents 
before her acute myocardial infarction. 
On admission to the hospital her blood 
sugar was 384 mg. per cent and insulin 
therapy was given. On the fourth hospital 
day the patient developed cardiogenic 
shock and glucagon therapy was started 
and insulin continued. Myocardial infarc- 
tion and glucagon would both be expected 
to increase the insulin requirement, and it 
was not possible to determine the specific 
effect of these two factors. No major change 
in insulin dosage was required. 
Side efects. The major side effect was 
nausea in 6 of the 16 patients. Nausea 
necessitated stopping the drug in one pa- 
tient, at his request, but was reasonably 
well tolerated in the other 5. Nausea ap- 
pears to be dose-related, but a specific dose 
level could not be determined due to indi- 
vidual patient variations. 
The first patient to receive a continuous 
infusion of glucagon had a hypoglycemic 
reaction. The glucagon had been prepared 
to run over a 24 hour period. Twenty hours 
after this solution was started, the patient 
developed atria1 flutter with variable A-V 
block and a ventricular rate of 140 to 160 
beats per minute. The patient became 
dyspneic, diaphoretic, and had no obtain- 
able blood pressure. A blood sample was 
collected and she was treated with 50 C.C. 
of a 50 per cent glucose solution; a 2 mg. 
bolus of glucagon and a fresh solution of 
glucagon was started. She also received 
0.4 mg. of lanatoside-C and 3 mg. of 
morphine sulfate intravenously. Labora- 
tory data from the blood sample revealed 
a blood glucose of 40 mg. per cent, serum 
sodium of 138 mEq. per liter, potassium of 
6.3 mEq. per liter, and blood urea nitrogen 
of 60 mg. per cent. One hour later she was 
comfortable with a ventricular rate of 90 
per minute and a blood pressure of 94/70 
mm. Hg. Two days later the patient under- 
went successful replacement of her mitral 
and aortic valves, though she did require 
glucagon therapy in the postoperative 
period. This observation suggested that 
glucagon deteriorates in solution at room 
temperature. When glucagon infusions fol- 
lowing this episode were freshly prepared, 
every 4 hours, no further hypoglycemia 
was seen. When glucagon was discontinued, 
a 5 per cent glucose-in-water infusion was 
continued for 3 to 4 hours to prevent reac- 
tive hypoglycemia, 
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Patient No. 5 received glucagon at the 
rate of 16 mg. per hour for 3 days and no 
toxic effects were seen in this patient nor 
in any other patients. There was no clinical 
evidence of tachyphylaxis. 
Discussion 
Glucagon is a polypeptide produced by 
the alpha cells of the pancreas and has 
been used clinically to treat hypoglycemia,6 
evaluate hepatic glycogen stores,’ and as a 
provocative test for pheochromocytoma.8 
Lucchesig and Glick and associates”’ have 
demonstrated that in the experimental 
animal beta-receptor blockade with pro- 
pranolol does not abolish the positive ino- 
tropic effect of glucagon. This was demon- 
strated in our first patient who was admitted 
to University Hospital with a low cardiac 
output syndrome, PAT with block due to 
digitalis intoxication, and a blood pressure 
of S/60 mm. Hg. Digitalis was stopped 
and since it was felt that the low cardiac 
output was secondary to the rapid rate, 
30 mg. of propranolol were given orally 
with conversion of the rhythm to normal. 
The oliguria and hypotension continued, 
however, and after the patient had received 
a total of 90 mg. of propranolol over a 24 
hour period, glucagon was started. Within 
15 minutes after starting glucagon, the 
blood pressure rose from 60/30 to 96/65 
mm, Hg, and over the next 8 hours urine 
output increased. Propranolol was then 
discontinued and no further arrhythmias 
were observed. Glucagon appears to be the 
drug of choice in the treatment of excessive 
cardiac depression due to beta-blocking 
agents. 
Glucagon is known to increase the re- 
lease of glucose from the liver and insulin 
from the pancreas. This results in an in- 
crease in peripheral glucose utilization and 
a transfer of extracellular potassium to the 
intracellular compartment with a resultant 
decrease in serum potassium. This effect 
was clearly demonstrated in the 4 patients 
who received glucagon without initial po- 
tassium supplements. This is of major con- 
cern in patients of the type studied here, all 
of whom were on digitalis and subject to 
the potential risk of arrhythmias should 
significant hypokalemia develop. As dem- 
onstrated this hazard can be handled by 
starting potassium supplements with the 
glucagon; however, frequent serum potas- 
sium determinations are essential in fol- 
lowing these patients since most (11 of 16) 
in this series have impaired renal function 
with elevated serum creatinines. 
Glucagon has a positive chronotropic 
effect” though this is not as marked as that 
seen with isoproterenol. This effect was not 
seen in this series of patients since most of 
them had severe cardiac decompensation 
and resultant tachycardias. When cardiac 
function was improved, apparently due to 
the inotropic effect of glucagon infusion, 
the heart rate decreased. This may be due 
to a decrease in sympathetic tone and 
decreased release of endogenous catechol- 
amines in response to an enhancement of 
cardiac function. The decrease in adre- 
nergic drive might explain the apparent 
effect of glucagon in preventing arrhyth- 
mias in these patients including those who 
had paroxysmal arrhythmias in the 24 hour 
period before glucagon was started. 
In this series no improvement was seen 
in patients with long-standing cardiogenic 
shock or in patients with chronic congestive 
heart failure who were maintaining a 
reasonable blood pressure. Glucagon would 
appear to be most useful in the treatment 
of acute hypotension and shock as seen in 
patients with cardiomyopathies and acute 
myocardial infarction, and in the low 
cardiac output state frequently seen follow- 
ing open-heart surgery. 
Summary 
A continuous infusion of glucagon in an 
average dose of 4 mg. per hour over several 
days produced distinct improvement in the 
clinical state of 12 of 16 patients. Improve- 
ment was noted by an increase in blood 
pressure and urinary output and decrease 
in dyspnea, pulmonary rgles, diaphoresis, 
and peripheral edema when present. Serum 
potassium must be carefully monitored. 
The rise in blood glucose has not been a 
clinical problem, No cardiac arrhythmias 
were induced by glucagon, and as cardiac 
function improved, the heart rate usually 
decreased. Nausea was the most frequent 
side effect, but no toxic effects or tachy- 
phylaxis were observed. Long-term therapy 
with glucagon infusion is both safe and 
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highly efficacious in selected patients with 
severe cardiovascular disease states and is 
the treatment of choice in cardiac de- 
compensation secondary to beta-blocking 
agents. 
Addendum 
Since this paper was written, Brogan, 
Kozonis, and Overy (Lancet 1:482, 1969), 
in consultation with the authors, used the 
method for continuous glucagon infusion 
with a successful result in 4 patients. 
The authors are grateful to: Drs. Thomas A. 
Preston and Richard D. Judge for their contribution 
of case material, to Drs. Herbert E. Sloan and 
Donald R. Kahn for their cooperation in the study 
of their patients, and to Dr. F. G. Henderson of 
Eli Lilly & Co., Indianapolis, Ind., who kindly 
supplied the giucagon used in this study. 
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